Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists are now a step closer to the development of new treatment options. The drugs target breast cancer caused due to higher levels of a protein called HER2. One study, published in the New England Journal of Medicine last week, found that adding the experimental drug tucatinib to a chemotherapy regimen could improve survival for adults. The other study, published in the same journal, found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor activity in patients with HER2-positive metastatic breast cancer.